|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.2100 - 0.2100|
|52 Week Range||0.1050 - 8.0000|
|Beta (5Y Monthly)||2.35|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Proceeds to Be Used to Ready Medical Devices for FDA 510k SubmissionsIRVINE, CA / ACCESSWIRE / August 20, 2020 / Odyssey Group International, Inc.
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Odyssey Reinsurance Company and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. Since 1 January 2019, Moody's practice has been to issue a press release following each periodic review to announce its completion.
IRVINE, CA / ACCESSWIRE / June 11, 2020 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, learned about certain promotional activity involving the trading of its common stock on June 9, 2020 when it was notified of such activity by OTC Markets ("OTC"). At that time, the Company was informed that promotional articles were published on the internet by a non-affiliated third-party source. The source of the promotional activity was two (2) online articles, by "MicroCapDaily" and "InsiderFinancial".